Mucocutaneous Langerhans cell histiocytosis (LCH) affects the skin and mucous membranes. When disease is symptomatic, a structured first-line treatment approach is used to guide management based on the extent of skin involvement.
Symptomatic cutaneous LCH is generally managed with topical therapy — the complete regimen, full range of options, and their applicability by disease extent are detailed in the full protocol.
Any degree of improvement in cutaneous lesions on skin examination is considered a treatment response.
DOI: 10.1182/blood.2021014343
Symptomatic cutaneous LCH is generally treated with topical or oral therapy.
Topical triamcinolone can be used for disease involving small areas of the skin.
Any degree of improvement in clinical or radiographic findings is considered a response.
View source ↗